Vericel (VCEL) Total Liabilities (2010 - 2026)
Vericel (VCEL) posted Total Liabilities of $132.8 million for Q2 2026, up 2.65% sequentially from $129.4 million in Q1 2026, and up 3.13% YoY from $128.8 million in Q2 2025.
Vericel (VCEL) Total Liabilities (2010 - 2026) Analysis & Trends
Vericel has reported Total Liabilities for 17 years, with the latest figure at $132.8 million in Q2 2026.
- Quarterly Total Liabilities rose 3.13% year-over-year to $132.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $132.8 million (up 3.13% YoY) and the FY2025 annual result came in at $133.3 million, down 5.28% from the prior year.
- Total Liabilities grew to $132.8 million in Q2 2026 per VCEL's latest filing, from $129.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $140.8 million in Q4 2024 and troughed at $67.8 million in Q1 2022.
- A 5-year average of $112.7 million and a median of $128.3 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 72.62% in 2024, then fell 5.28% in 2025.
- Over 5 years, Total Liabilities stood at $80.7 million in 2022, then soared by 58.19% to $127.7 million in 2023, then rose by 10.22% to $140.8 million in 2024, then dropped by 5.28% to $133.3 million in 2025, then slipped by 0.38% to $132.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $132.8 million, $129.4 million, and $133.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 132.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132.83 Mn |
| Mar 31, 2026 | 129.40 Mn |
| Dec 31, 2025 | 133.33 Mn |
| Sep 30, 2025 | 131.42 Mn |
| Jun 30, 2025 | 128.80 Mn |
| Mar 31, 2025 | 129.10 Mn |
| Dec 31, 2024 | 140.76 Mn |
| Sep 30, 2024 | 132.93 Mn |
| Jun 30, 2024 | 133.86 Mn |
| Mar 31, 2024 | 122.77 Mn |
| Dec 31, 2023 | 127.71 Mn |
| Sep 30, 2023 | 113.75 Mn |
| Jun 30, 2023 | 111.78 Mn |
| Mar 31, 2023 | 71.12 Mn |
| Dec 31, 2022 | 80.73 Mn |
| Sep 30, 2022 | 70.18 Mn |
| Jun 30, 2022 | 70.00 Mn |
| Mar 31, 2022 | 67.80 Mn |
| Dec 31, 2021 | 73.24 Mn |
| Sep 30, 2021 | 67.36 Mn |